Izumi City General Hospital

InstitutionResearch output, impact & collaborations

Izumi City General Hospital is a research organisation in Osaka, JP. OpenAlex records 1,428 works and 43,620 citations for it. 439 researchers list it as their most recent affiliation.

1,428

Works

43,620

Citations

439

Researchers

113

Avg h-index

IDs:ROR OpenAlex

How has Izumi City General Hospital's publication output changed over time?

ScholarIQpublication output · 2007–2023

Output grew0% over the shown period — from 1 works in 2007 to 1 in 2023.

2007201020122016201720182020202120222023

What are the most-cited papers on Izumi City General Hospital?

ScholarIQmost cited works

<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Jeffrey A. Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi, Youngchul Song, Courtney Hyland, Joon Oh Park, Neal I. Lindeman, Christopher-Michael Gale, Xiao‐Jun Zhao, James G. Christensen, Takayuki Kosaka, Alison J. Holmes, Andrew M. Rogers, Federico Cappuzzo, Tony Mok, Charles Lee, Bruce E. Johnson, Lewis C. Cantley, Pasi A. Jänne

Science. 20074,477 CitationsOPEN ACCESS

Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial

Hisashi Saji, Morihito Okada, Masahiro Tsuboi, Ryu Nakajima, Kenji Suzuki, Keiju Aokage, Tadashi Aoki, Jiro Okami, Ichiro Yoshino, Hiroyuki Ito, Norihito Okumura, Masafumi Yamaguchi, Norihiko Ikeda, Masashi Wakabayashi, Kenichi Nakamura, Haruhiko Fukuda, Shinichiro Nakamura, Tetsuya Mitsudomi, Shun‐ichi Watanabe, Hisao Asamura

The Lancet. 20221,710 Citations

EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors

Young Lim Choi, Manabu Soda, Yoshihiro Yamashita, Toshihide Ueno, Junpei Takashima, Takahiro Nakajima, Yasushi Yatabe, Kengo Takeuchi, Toru Hamada, Hidenori Haruta, Yuichi Ishikawa, Hideki Kimura, Tetsuya Mitsudomi, Yoshiro Tanio, Hiroyuki Mano

New England Journal of Medicine. 20101,185 CitationsOPEN ACCESS

Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial

Toyoaki Hida, Hiroshi Nokihara, Masashi Kondo, Young Hak Kim, Koichi Azuma, Takashi Seto, Yuichi Takiguchi, Makoto Nishio, Hiroshige Yoshioka, Fumio Imamura, Katsuyuki Hotta, Satoshi Watanabe, Kōichi Goto, Miyako Satouchi, Toshiyuki Kozuki, Takehito Shukuya, Kazuhiko Nakagawa, Tetsuya Mitsudomi, Nobuyuki Yamamoto, T. Asakawa, Ryoichi Asabe, Tomohiro Tanaka, Tomohide Tamura

The Lancet. 2017921 Citations

Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer

John V. Heymach, David H. Harpole, Tetsuya Mitsudomi, Janis M. Taube, Gabriella Gálffy, Maximilian J. Hochmair, Thomas Winder, Р. А. Зуков, Gabriel Garbaos, Shugeng Gao, Hiroaki Kuroda, Gyula Ostoros, Tho V. Tran, Jian You, Kang‐Yun Lee, Lorenzo Antonuzzo, Zsolt Pápai-Székely, Hiroaki Akamatsu, Bivas Biswas, Alexander I. Spira, Jeffrey Crawford, Ha Le, Mike Aperghis, Gary J. Doherty, Helen Mann, Tamer M. Fouad, Martin Reck

New England Journal of Medicine. 2023724 CitationsOPEN ACCESS